Top

Published in:

01-08-2011 | PRECLINICAL STUDIES

AC480, formerly BMS-599626, a pan Her inhibitor, enhances radiosensitivity and radioresponse of head and neck squamous cell carcinoma cells in vitro and in vivo

Authors: Mylin A. Torres, Uma Raju, David Molkentine, Oliver Riesterer, Luka Milas, K. Kian Ang

Published in: Investigational New Drugs | Issue 4/2011

Summary

Purpose: The present study investigated the effect of AC480, a small molecule pan-HER tyrosine kinase inhibitor, on in vitro radiosensitivity and in vivo radioresponse of a human head and neck squamous cell carcinoma cell line. Methods: HN-5 cells were exposed to γ-radiation with and without AC480 and assayed for proliferation, clonogenic survival, apoptosis, cell cycle distribution, and DNA damage. The cells were analyzed by immunoprecipitation and western blotting for proteins involved in apoptosis, cell cycle regulation, and the EGFR pathway. The effect of AC480 on tumor radioresponse was assessed by tumor growth delay assay using HN5 tumor xenografts generated in nude mice. Results: At the molecular level, in HN-5 cells the agent inhibited the expression of pEGFR, pHER2, cyclins D and E, pRb, pAkt, pMAPK, pCDK1 and 2, CDK 6, and Ku70 proteins. The drug also induced accumulation of cells in the G1 cell cycle phase, inhibited cell growth, enhanced radiosensitivity, and prolonged the presence of γ-H₂AX foci up to 24 h after radiation. AC480 did not increase the percentage of cells undergoing radiation-induced apoptosis. The drug given before and during irradiation improved the radioresponse of HN5 tumors in vivo. Conclusion: AC480 significantly enhanced the radiosensitivity of HN-5 cells, expressing both EGFR and Her2. The mechanisms involved in the enhancement included cell cycle redistribution and inhibition of DNA repair. Both in vitro and in vivo data from our study suggest that AC480 has potential to increase tumor response to radiotherapy.

Akimoto T, Hunter NR, Buchmiller L, Mason K, Ang KK, Milas L (1999) Inverse relationship between epidermal growth factor receptor expression and radiocurability of murine carcinomas. Clin Cancer Res 5:2884–2890PubMed

Ang KK, Berkey BA, Tu X, Zhang HZ, Katz R, Hammond EH et al (2002) Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. Cancer Res 62:7350–7356PubMed

Huang SM, Bock JM, Harari PM (1999) Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck. Cancer Res 59:1935–1940PubMed

Huang SM, Harari PM (2000) Modulation of radiation response after epidermal growth factor receptor blockade in squamous cell carcinomas: inhibition of damage repair, cell cycle kinetics, and tumor angiogenesis. Clin Cancer Res 6:2166–2174PubMed

Milas L, Akimoto T, Hunter NR, Mason KA, Buchmiller L, Yamakawa M et al (2002) Relationship between cyclin D1 expression and poor radioresponse of murine carcinomas. Int J Radiat Oncol Biol Phys 52:514–521PubMedCrossRef

Schmidt-Ullrich RK, Mikkelsen RB, Dent P, Todd DG, Valerie K, Kavanagh BD et al (1997) Radiation-induced proliferation of the human A431 squamous carcinoma cells is dependent on EGFR tyrosine phosphorylation. Oncogene 15:1191–1197PubMedCrossRef

Schmidt-Ullrich RK, Valerie K, Fogleman PB, Walters J (1996) Radiation-induced autophosphorylation of epidermal growth factor receptor in human malignant mammary and squamous epithelial cells. Radiat Res 145:81–85PubMedCrossRef

Sheridan MT, O’Dwyer T, Seymour CB, Mothersill CE (1997) Potential indicators of radiosensitivity in squamous cell carcinoma of the head and neck. Radiat Oncol Investig 5:180–186PubMedCrossRef

Liang K, Ang KK, Milas L, Hunter N, Fan Z (2003) The epidermal growth factor receptor mediates radioresistance. Int J Radiat Oncol Biol Phys 57:246–254PubMedCrossRef

10.

Dittmann K, Mayer C, Fehrenbacher B, Schaller M, Raju U, Milas L et al (2005) Radiation-induced epidermal growth factor receptor nuclear import is linked to activation of DNA-dependent protein kinase. J Biol Chem 280:31182–31189PubMedCrossRef

11.

Dittmann KH, Mayer C, Ohneseit PA, Raju U, Andratschke NH, Milas L et al (2008) Celecoxib induced tumor cell radiosensitization by inhibiting radiation induced nuclear EGFR transport and DNA-repair: a COX-2 independent mechanism. Int J Radiat Oncol Biol Phys 70:203–212PubMedCrossRef

12.

Dittmann K, Mayer C, Rodemann HP (2005) Inhibition of radiation-induced EGFR nuclear import by C225 (Cetuximab) suppresses DNA-PK activity. Radiother Oncol 76:157–161PubMedCrossRef

13.

Walker F, Zhang HH, Burgess AW (2007) Identification of a novel EGF-sensitive cell cycle checkpoint. Exp Cell Res 313:511–526PubMedCrossRef

14.

Albanell J, Codony-Servat J, Rojo F, Del Campo JM, Sauleda S, Anido J et al (2001) Activated extracellular signal-regulated kinases: association with epidermal growth factor receptor/transforming growth factor alpha expression in head and neck squamous carcinoma and inhibition by anti-epidermal growth factor receptor treatments. Cancer Res 61:6500–6510PubMed

15.

Huang S, Armstrong EA, Benavente S, Chinnaiyan P, Harari PM (2004) Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor. Cancer Res 64:5355–5362PubMedCrossRef

16.

Milas L, Fan Z, Andratschke NH, Ang KK (2004) Epidermal growth factor receptor and tumor response to radiation: in vivo preclinical studies. Int J Radiat Oncol Biol Phys 58:966–971PubMedCrossRef

17.

Milas L, Fang FM, Mason KA, Valdecanas D, Hunter N, Koto M et al (2007) Importance of maintenance therapy in C225-induced enhancement of tumor control by fractionated radiation. Int J Radiat Oncol Biol Phys 67:568–572PubMedCrossRef

18.

Milas L, Mason K, Hunter N, Petersen S, Yamakawa M, Ang K et al (2000) In vivo enhancement of tumor radioresponse by C225 antiepidermal growth factor receptor antibody. Clin Cancer Res 6:701–708PubMed

19.

Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB et al (2006) Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 354:567–578PubMedCrossRef

20.

Beckhardt RN, Kiyokawa N, Xi L, Liu TJ, Hung MC, el-Naggar AK et al (1995) HER-2/neu oncogene characterization in head and neck squamous cell carcinoma. Arch Otolaryngol Head Neck Surg 121:1265–1270PubMed

21.

Cavalot A, Martone T, Roggero N, Brondino G, Pagano M, Cortesina G (2007) Prognostic impact of HER-2/neu expression on squamous head and neck carcinomas. Head Neck 29:655–664PubMedCrossRef

22.

Ekberg T, Nestor M, Engstrom M, Nordgren H, Wester K, Carlsson J et al (2005) Expression of EGFR, HER2, HER3, and HER4 in metastatic squamous cell carcinomas of the oral cavity and base of tongue. Int J Oncol 26:1177–1185PubMed

23.

Wong TW, Lee FY, Yu C, Luo FR, Oppenheimer S, Zhang H et al (2006) Preclinical antitumor activity of BMS-599626, a pan-HER kinase inhibitor that inhibits HER1/HER2 homodimer and heterodimer signaling. Clin Cancer Res 12:6186–6193PubMedCrossRef

24.

Raju U, Gumin GJ, Noel F, Tofilon PJ (1998) IkappaBalpha degradation is not a requirement for the X-ray-induced activation of nuclear factor kappaB in normal rat astrocytes and human brain tumour cells. Int J Radiat Biol 74:617–624PubMedCrossRef

25.

Akli S, Van Pelt CS, Bui T, Multani AS, Chang S, Johnson D et al (2007) Overexpression of the low molecular weight cyclin E in transgenic mice induces metastatic mammary carcinomas through the disruption of the ARF-p53 pathway. Cancer Res 67:7212–7222PubMedCrossRef

26.

Akli S, Zheng PJ, Multani AS, Wingate HF, Pathak S, Zhang N et al (2004) Tumor-specific low molecular weight forms of cyclin E induce genomic instability and resistance to p21, p27, and antiestrogens in breast cancer. Cancer Res 64:3198–3208PubMedCrossRef

27.

Bales E, Mills L, Milam N, McGahren-Murray M, Bandyopadhyay D, Chen D et al (2005) The low molecular weight cyclin E isoforms augment angiogenesis and metastasis of human melanoma cells in vivo. Cancer Res 65:692–697PubMed

28.

Corin I, Di Giacomo MC, Lastella P, Bagnulo R, Guanti G, Simone C (2006) Tumor-specific hyperactive low-molecular-weight cyclin E isoforms detection and characterization in non-metastatic colorectal tumors. Cancer Biol Ther 5:198–203PubMedCrossRef

29.

Davidson B, Skrede M, Silins I, Shih IeM, Trope CG, Florenes VA (2007) Low-molecular weight forms of cyclin E differentiate ovarian carcinoma from cells of mesothelial origin and are associated with poor survival in ovarian carcinoma. Cancer 110:1264–1271PubMedCrossRef

30.

Keyomarsi K, Tucker SL, Buchholz TA, Callister M, Ding Y, Hortobagyi GN et al (2002) Cyclin E and survival in patients with breast cancer. N Engl J Med 347:1566–1575PubMedCrossRef

31.

Milne AN, Carvalho R, Jansen M, Kranenbarg EK, van de Velde CJ, Morsink FM et al (2008) Cyclin E low molecular weight isoforms occur commonly in early-onset gastric cancer and independently predict survival. J Clin Pathol 61:311–316PubMedCrossRef

Title: AC480, formerly BMS-599626, a pan Her inhibitor, enhances radiosensitivity and radioresponse of head and neck squamous cell carcinoma cells in vitro and in vivo
Authors: Mylin A. Torres
Uma Raju
David Molkentine
Oliver Riesterer
Luka Milas
K. Kian Ang
Publication date: 01-08-2011
Publisher: Springer US
Published in: Investigational New Drugs / Issue 4/2011
Print ISSN: 0167-6997
Electronic ISSN: 1573-0646
DOI: https://doi.org/10.1007/s10637-010-9389-3

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Summary

Please log in to get access to this content

Other articles of this Issue 4/2011

A phase II study of isoflavones, erlotinib, and gemcitabine in advanced pancreatic cancer

A novel structural derivative of natural alkaloid ellipticine, MDPSQ, induces necrosis in leukemic cells

Baicalin induces human mucoepidermoid carcinoma Mc3 cells apoptosis in vitro and in vivo

Suppressive effects of liquid crystal compounds on the growth of the A549 human lung cancer cell line

LYP, a novel bestatin derivative, inhibits cell growth and suppresses APN/CD13 activity in human ovarian carcinoma cells more potently than bestatin

The anti-proliferative side effects of AEE788, a tyrosine kinase inhibitor blocking both EGF- and VEGF-receptor, are liver-size-dependent after partial hepatectomy in rats

Keynote webinar | Spotlight on antibody–drug conjugates in cancer